Skip to main content
OpenTrials
Completed

NCT Number: NCT01406392

Sublingual Misoprostol for Induction of Labor

The purpose of this study is to compare effectiveness and safety of a sublingual misoprostol 12,5 mcg with vaginal misoprostol 25 mcg for induction of labour with an alive and term fetus.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

15 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Instituto de Medicina Integral Professor Fernando Figueira (IMIP)

Recife, Pernambuco, 50070-550, Brazil

About this study

Several methods for induction of labour are available. However, the most effective and with less frequency of adverse effects is still unknown. Vaginal misoprostol has been used frequently to induce labour but other routes of administrations have been proposed, such as oral and sublingual. The purpose of this study is to compare effectiveness and safety of sublingual misoprostol 12,5 mcg with vaginal misoprostol 25 mcg administration for induction of labour with an alive and term fetus. A randomized controlled double-blind trial will be carried in two hospitals: Instituto de Medicina Integral Prof. Fernando Figueira and Universidade Federal do Ceará and Instituto de Saúde Elpídio de Almeida, from July 2014 to November 2016. A total of 150 patients must be enrolled. Inclusion criteria are: a) indication for labour induction; b) term pregnancy with alive fetus; Bishop score less than six. Exclusion criteria are: a) previous uterine scar; b) nonvertex presentation; c) non-reassuring fetal status; d) fetal anomalies; e) fetal growth restriction; f) genital bleeding; g) tumors, malformations and/or ulcers of vulva, perineum or vagina. They will be randomized to receive a sublingual misoprostol 12,5 mcg with vaginal placebo tablet or sublingual placebo with vaginal misoprostol 25 mcg tablet. Vaginal tablets will have 25mcg of misoprostol or placebo. Sublingual tablet will have 12,5mcg or placebo. Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets. Primary outcome will be the frequency of tachysystole. Secondary outcomes will be vaginal delivery within 24 hours, hyperstimulation syndrome, cesarean section, severe neonatal morbidity or perinatal death, serious maternal morbidity or maternal death, need of oxytocin for augmentation of labour, number of misoprostol doses needed to bring on labour, interval from first dose to labour and first dose to delivery, failed induction, uterine rupture, need of labour analgesia, instrumental delivery, side effects, maternal death, meconium, non-reassuring fetal heart rate, Apgar scores less than seven at 1st and 5th minutes, admission at neonatal intensive care unit, neonatal encephalopaty, perinatal death and women not satisfied.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Indication for labour induction
  • Term pregnancy with alive fetus
  • Bishop score less than six

Exclusion criteria

  • Previous uterine scar
  • Nonvertex presentation
  • Non-reassuring fetal status
  • Fetal anomalies
  • Fetal growth restriction
  • Genital bleeding
  • Tumors, malformations and/or ulcers of vulva, perineum or vagina

Treatment and study plan

Misoprostol 25mcg

Drug

Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets.

Other names: Prostokos Cytotec

Sublingual misoprostol

Drug

Sublingual misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 100mcg or eight tablets

Other names: Prostokos, Cytotec

Primary outcomes

  1. Frequency of taquissistoly

    Time frame: 48 hours

    during 48 hours the presence of taquissistoly will be observed

Secondary outcomes

  1. Hyperstimulation Syndrome

    Time frame: 48 hours

    during 48 hours the presence of hyperstimulation syndrome will be observed

  2. changes in the cervix at 12 and 24 hours

    Time frame: 12 and 24 hours

    changes in the cervix

  3. failure to achieve vaginal delivery within 12 and 24 hours

    Time frame: 12 and 24 hours

    failure to achieve vaginal delivery

  4. the mother's preferred route of administration

    Time frame: after 48 hours

    Ask to mother what route of administratios was the best for her

  5. time between the first dose and the onset of labour and delivery

    Time frame: after 48 hours

    to avaluete the time between the first dose and the onset of labour and delivery

  6. duration of labour

    Time frame: after 48 hours

    to avaluete the time of duration of labour

  7. need for oxytocin

    Time frame: after 48 hours

    to avaluete the use of oxytocin during the labour

  8. failed induction of labour

    Time frame: after 48 hours

    to avaluete the faliled induction of labor

  9. Caesarean section and the indications for this procedure

    Time frame: after 48 hours

    to avaluete the number of Caesarean section and the indications for this procedure

  10. need for epidural anaesthesia

    Time frame: after 48 hours

    to avaluete the need for epidural anaesthesia

  11. maternal side effects (nausea, vomiting, diarrhoea, postpartum haemorrhage and fever);

    Time frame: after 48 hours

    to avaluete if occurred any case of maternal side effects (nausea, vomiting, diarrhoea, postpartum haemorrhage and fever);

  12. severe maternal morbidity (uterine rupture, sepsis and admission to intensive care unit) or maternal death

    Time frame: 48 hours

    to avaluete severe maternal morbidity (uterine rupture, sepsis and admission to intensive care unit) or maternal death

  13. meconium in the amniotic fluid

    Time frame: 48 hours

    to avaluete meconium in the amniotic fluid

  14. non-reassuring foetal heart rate

    Time frame: 48 hours

    non-reassuring foetal heart rate

  15. one- and five-minute Apgar scores <7

    Time frame: after 48 hours

    to avaluete one- and five-minute Apgar scores <7

  16. admission of the newborn to a neonatal intensive care unit

    Time frame: after 48 hours

    to avaluete admission of the newborn to a neonatal intensive care unit

  17. need for neonatal resuscitation

    Time frame: after 48 hours

    to avaluete the need for neonatal resuscitation

  18. severe neonatal morbidity (convulsions and neonatal asphyxiation) or perinatal death.

    Time frame: after 48 hours

    to avaluete severe neonatal morbidity (convulsions and neonatal asphyxiation) or perinatal death.

Sponsors and collaborators

Lead sponsor

Professor Fernando Figueira Integral Medicine Institute

Other

Collaborators

  • Maternidade Escola Assis Chateaubriand

Registry information

Official study title

Sublingual Misoprostol 12,5 mcg Versus Vaginal Misoprostol 25 mcg for Induction of Labour of Alive and Term Fetus : Randomized Controlled Trial

Acronym: SUBMISO

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Aug 1, 2011
Registry last updated
Sep 18, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.